Certara, Inc. filings document the public-company record for a Nasdaq-listed provider of biosimulation software and model-informed drug development services. Its 8-K reports include operating and financial results, guidance-related exhibits, material-event disclosures, credit agreement amendments and the completed sale of its global medical writing and related regulatory services business.
Proxy and governance filings describe annual-meeting matters, board composition, executive transitions and stockholder voting procedures. The record also identifies Certara's common stock, capital-structure disclosures and clinical or regulatory disclosures tied to software, services, regulatory science and clinical-development support.
Certara director Nancy Killefer increased her equity position through routine equity compensation events. On May 14, 2026, 15,757 restricted stock units granted on May 21, 2025 vested and were converted into 15,757 shares of common stock. On the same date, she received a new grant of 33,222 restricted stock units under Certara’s 2020 Incentive Plan, each representing one future share of common stock. Following these transactions, she directly holds 51,846 shares of common stock and 33,222 restricted stock units.
Certara, Inc. director Rosemary A. Crane exercised restricted stock units into common shares as part of her equity compensation. On May 14, 2026, 15,757 restricted stock units granted under the Certara, Inc. 2020 Incentive Plan vested and were converted into 15,757 shares of common stock. Following the transaction, she directly owned 45,672 shares of Certara common stock. No open-market purchases or sales were reported in this filing.
Certara director Matthew M. Walsh reported equity compensation activity involving restricted stock units (RSUs) and common stock. On May 14, 2026, 15,757 RSUs vested and were converted into 15,757 shares of Certara common stock under the 2020 Incentive Plan, increasing his direct common stock holdings to 213,316 shares.
On the same date, he also received a new grant of 33,222 RSUs under the 2020 Incentive Plan, each RSU representing a right to receive one share of common stock. These new RSUs vest on the earlier of the one-year anniversary of the grant date or the date of Certara’s next annual meeting.
Certara, Inc. reported that executive Robert Aspbury, President of Predictive Tech, received new equity awards on May 11, 2026. He was granted 129,629 Performance Stock Units (PSUs) and two Restricted Stock Unit (RSU) awards covering 246,913 and 86,419 underlying shares of common stock.
Footnotes explain that PSUs can pay out between 0% and 200% of the target amounts based on Certara’s total shareholder return through periods ending March 31, 2028 and March 31, 2029. The RSUs vest in three equal installments on April 1, 2027, April 1, 2028, and April 1, 2029. A separate block of 68,348 PSUs was granted and then fully canceled in an issuer disposition, reflecting an amendment of earlier awards.
Certara, Inc. reported equity compensation changes for President and Chief Commercial Officer Leif E. Pedersen. On May 11, 2026, he received grants of 111,111 performance stock units and 74,074 restricted stock units at no cash cost, each unit tied to one share of common stock or its cash equivalent.
The new performance stock units can ultimately deliver between 0% and 200% of the target share amount based on Certara’s total shareholder return through periods ending on March 31, 2028 and March 31, 2029 under the company’s long-term incentive plans. The restricted stock units are scheduled to vest in three equal installments on April 1, 2027, April 1, 2028, and April 1, 2029. The filing also shows a prior grant of 68,348 performance stock units was returned to the issuer, leaving no units outstanding from that earlier award.
Certara, Inc. reported compensation-related equity awards for Chief Human Resources Officer Rona Anhalt. On May 11, 2026, she received grants of 92,592 performance stock units and 61,728 restricted stock units, each representing rights to receive shares of common stock under the company’s 2020 Incentive Plan.
The PSUs can ultimately pay out between 0% and 200% of the target amount based on Certara’s total shareholder return over performance periods ending on March 31, 2028 and March 31, 2029. The RSUs are scheduled to vest in three equal installments on April 1, 2027, April 1, 2028, and April 1, 2029. The filing also records a 43,938-unit PSU disposition to the issuer, reducing that specific grant’s balance to zero.
Certara, Inc. CEO Jon Matthew Resnick reported equity compensation activity and related tax withholding. On May 11, 2026, he exercised 59,766 restricted stock units into common shares and 24,377 shares were withheld at $6.31 per share to cover tax obligations, leaving 35,389 common shares directly held.
On the same date, he received several new awards under the 2020 Incentive Plan: 728,405 RSUs vesting in 2027 and 2028, 493,827 RSUs vesting in 2027 and 2029, and 179,299 RSUs with tranches through 2029. He was also granted 740,740 and 268,949 performance stock units that can pay out between 0% and 200% of target if Certara’s stock reaches specified price thresholds by April 1, 2028 and March 31, 2029.
Certara, Inc. reported new equity awards for SVP and General Counsel Daniel Corcoran. On May 11, 2026, he received grants of 111,111 performance stock units and 74,074 restricted stock units, each representing rights to receive common shares under the company’s 2020 Incentive Plan.
The PSUs can ultimately settle at 0% to 200% of the target amounts based on Certara’s total shareholder return through periods ending March 31, 2028 and March 31, 2029. The RSUs are scheduled to vest in three equal installments on April 1, 2027, April 1, 2028, and April 1, 2029. The filing also records a 48,820‑unit PSU grant and a matching 48,820‑unit disposition back to the issuer.
Certara, Inc. Chief Financial Officer John E. Gallagher reported equity-based compensation awards tied to the company’s long-term incentive plans. On May 11, 2026, he received grants of 194,444 performance stock units and 129,629 restricted stock units, each representing rights to receive common shares at no purchase price.
The restricted stock units are scheduled to vest in three equal installments on April 1, 2027, April 1, 2028, and April 1, 2029. He also received an additional 102,522 performance stock units grant and simultaneously reported a disposition of a prior 102,522 performance stock units award back to the issuer, leaving no remaining units from that earlier grant. The new performance stock units can ultimately deliver between 0% and 200% of the target share amounts based on total shareholder return performance through periods ending March 31, 2028 and March 31, 2029.
Certara, Inc. reported flat revenue but a swing to loss in its latest quarter. For the three months ended March 31, 2026, revenue was $106.9 million, up slightly from $106.0 million a year earlier, while net results moved from $4.7 million profit to a $8.8 million loss, or basic and diluted loss of $0.06 per share.
Operating income declined to a $4.3 million loss as general and administrative and research and development expenses increased. Cash and cash equivalents fell from $189.4 million at year-end to $149.5 million, driven largely by $40 million of share repurchases and ongoing investment in software development.
The company ended the quarter with $294.8 million of term-loan debt and total stockholders’ equity of $1.02 billion. Bookings were $115.3 million with a software net retention rate of 106.1%, indicating expansion within the existing customer base. After quarter end, Certara closed the sale of its global medical writing and related regulatory services business, expecting to recognize a loss estimated between $28.9 million and $53.7 million on that divestiture.